Business Wire

THALES

16.4.2024 09:01:32 CEST | Business Wire | Press release

Share
Bots Now Make Up Nearly Half of All Internet Traffic Globally

Thales, the cybersecurity leader that protects critical applications, APIs, and data, anywhere at scale, today announced the release of the 2024 Imperva Bad Bot Report, a global analysis of automated bot traffic across the internet. Nearly half (49.6%) of all internet traffic came from bots in 2023—a 2% increase over the previous year, and the highest level Imperva has reported since it began monitoring automated traffic in 2013.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416225637/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

For the fifth consecutive year, the proportion of web traffic associated with bad bots grew to 32% in 2023, up from 30.2% in 2022, while traffic from human users decreased to 50.4%. Automated traffic is costing organizations billions (USD) annually due to attacks on websites, APIs, and applications.

“Bots are one of the most pervasive and growing threats facing every industry,” says Nanhi Singh, General Manager, Application Security at Imperva, a Thales company. “From simple web scraping to malicious account takeover, spam, and denial of service, bots negatively impact an organization’s bottom line by degrading online services and requiring more investment in infrastructure and customer support. Organizations must proactively address the threat of bad bots as attackers sharpen their focus on API-related abuses that can lead to account compromise or data exfiltration.”

Key trends identified in the 2024 Imperva Bad Bot Report include:

  • Global average of bad bot traffic reached 32%: Ireland (71%), Germany (67.5%), and Mexico (42.8%), saw the highest levels of bad bot traffic in 2023. The US also saw a slightly higher ratio of bad bot traffic at 35.4% compared to 2022 (32.1%).
  • Growing use of generative AI connected to the rise in simple bots: Rapid adoption of generative AI and large language models (LLMs) resulted in the volume of simple bots increasing to 39.6% in 2023, up from 33.4% in 2022. The technology uses web scraping bots and automated crawlers to feed training models, while enabling nontechnical users to write automated scripts for their own use.
  • Account takeover is a persistent business risk: Account takeover (ATO) attacks increased 10% in 2023, compared to the same period in the prior year. Notably, 44% of all ATO attacks targeted API endpoints, compared to 35% in 2022. Of all login attempts across the internet, 11% were associated with account takeover. The industries that saw the highest volume of ATO attacks in 2023 were Financial Services (36.8%), Travel (11.5%), and Business Services (8%).
  • APIs are a popular vector for attack: Automated threats caused a significant 30% of API attacks in 2023. Among them, 17% were bad bots exploiting business logic vulnerabilities—a flaw within the API’s design and implementation that allows attackers to manipulate legitimate functionality and gain access to sensitive data or user accounts. Cybercriminals use automated bots to find and exploit APIs, which act as a direct pathway to sensitive data, making them a prime target for business logic abuse.
  • Every industry has a bot problem: For a second consecutive year, Gaming (57.2%) saw the largest proportion of bad bot traffic. Meanwhile, Retail (24.4%), Travel (20.7%), and Financial Services (15.7%) experienced the highest volume of bot attacks. The proportion of advanced bad bots, those that closely mimic human behavior and evade defenses, was highest on Law & Government (75.8%), Entertainment (70.8%), and Financial Services (67.1%) websites.
  • Bad bot traffic originating from residential ISPs grows to 25.8%: Early bad bot evasion techniques relied on masquerading as a user agent (browser) commonly used by legitimate human users. Bad bots masquerading as mobile user agents accounted for 44.8% of all bad bot traffic in the past year, up from 28.1% just five years ago. Sophisticated actors combine mobile user agents with the use of residential or mobile ISPs. Residential proxies allow bot operators to evade detection by making it appear as if the origin of the traffic is a legitimate, ISP-assigned residential IP address.

“Automated bots will soon surpass the proportion of internet traffic coming from humans, changing the way that organizations approach building and protecting their websites and applications,” continued Singh. “As more AI-enabled tools are introduced, bots will become omnipresent. Organizations must invest in bot management and API security tools to manage the threat from malicious, automated traffic.”

Additional Information:

  • Download a copy of the 2024 Imperva Bad Bot Report for additional insights.
  • See how Imperva Advanced Bot Protection, API Security, and Client-Side Protection can protect websites, mobile applications, and APIs from automated attacks and fraud without affecting the flow of business-critical traffic.
  • Read the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416225637/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

Bending Spoons has entered into a definitive agreement to acquire Airtable for $1.285 billion4.8.2026 08:30:00 CEST | Press release

Bending Spoons S.p.A. (NASDAQ: BSP) announced that it has entered into a definitive agreement to acquire Airtable, in an all-cash transaction that values Airtable at an enterprise value of $1.285 billion, which, together with Airtable’s current net cash-and-cash-equivalents balance, implies an equity value of approximately $2.25 billion. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals. “We’re looking forward to welcoming Airtable into Bending Spoons,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Airtable is a pioneering brand reshaping how teams organize data and manage critical workflows. The value being delivered is reflected in annual recurring revenue growing over 20% YoY to approximately $480 million as of June 2026, and joining forces with Bending Spoons will accelerate innovation even further. We’re committed to investing in Airtable for the long run, and doubling down on its core strength: bringing teams and wor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye